Real World Evidence of the Efficacy and Safety of FOQUEST

Inclusion Criteria:

1. Pediatric: Male or non-pregnant, non-nursing female patients the age of 6 to less than
2. Adults: Male or non-pregnant, non-nursing female patients the age of 18 or older.
3. Diagnosed with ADHD (inattentive, hyperactive or combined-type) who are deemedeligible to receive treatment with FOQUEST or VYVANSE, as per the respective ProductMonograph.
4. Mentally and physically competent to provide informed consent, or assent and able andwilling to comply with the study protocol, including the study duration.

Exclusion Criteria: Potential patients who meet any of the contraindications or warnings detailed in therespective Canadian Product Monographs are excluded from participation in the study:

1. Having a true allergy to methylphenidate or amphetamines or sympathomimetic amines,history of serious adverse reactions to methylphenidate or amphetamines or be known tobe non-responsive to methylphenidate or amphetamine treatment. Non-response is definedas methylphenidate or amphetamine use at various doses for a phase of at least fourweeks at each dose with little or no clinical benefit in the past 10 years.
2. Females of child-bearing potential (FOCP) who are pregnant, planning on becomingpregnant or breast feeding.
3. Having a history of hyperthyroidism, thyrotoxicosis, advanced arteriosclerosis, severerenal insufficiency or glaucoma.
4. Having structural cardiac abnormalities, symptomatic cardiovascular disease ormoderate to severe hypertension.
5. Currently, or within the past 14 days, receiving MAO inhibitors.
6. Having a primary diagnosis of bipolar disorder, as assessed at Visit 1.
7. Currently receiving any investigational drug, or have received an investigational drugin the previous month.
8. Having a history of drug or alcohol abuse or dependence.
9. Currently considered a suicide risk by the Investigator.